Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

University of Toronto

$155,800.00

Minimally-Invasive Method of Selectively Activating Posterior Tibial Nerve Afferents for Treating Overactive Bladder

EF 2014-15

Résumé
Overactive bladder (OAB) is an incurable urinary disorder that affects approximately 15% of the adult population. Recent studies show that the OAB is particularly prevalent in people over the age of 65. Although there are several treatment options available to patients, effective long-term treatment of OAB symptoms remains a major clinical challenge. In this application, we propose to commercialize novel nerve stimulation technology that will significantly enhance an emerging OAB therapy called posterior tibial nerve stimulation (PTNS). Our approach will provide patients who cannot tolerate drug therapy or spinal cord stimulation with a more simplified method of treating OAB symptoms.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
325204
Name
Yoo Paul
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Minimally-Invasive Method of Selectively Activating Posterior Tibial Nerve Afferents for Treating Overactive Bladder
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$155,800
Cihrequipment2
$4,000
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Electrical Neuromodulation; Overactive Bladder; Plantar Nerve; Posterior Tibial Nerve Stimulation; Transcutaneous Electrical Nerve Stimulation
Abstract
Overactive bladder (OAB) is an incurable urinary disorder that affects approximately 15% of the adult population. Recent studies show that the OAB is particularly prevalent in people over the age of 65. Although there are several treatment options available to patients, effective long-term treatment of OAB symptoms remains a major clinical challenge. In this application, we propose to commercialize novel nerve stimulation technology that will significantly enhance an emerging OAB therapy called posterior tibial nerve stimulation (PTNS). Our approach will provide patients who cannot tolerate drug therapy or spinal cord stimulation with a more simplified method of treating OAB symptoms.
Competitiondate
201502
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yoo, Paul
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $155,800~ $4,000~